{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:31:57Z","timestamp":1792222317610,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.vaccine.2017.06.030","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T11:00:41Z","timestamp":1500894041000},"page":"4761-4768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2 million young girls in France"],"prefix":"10.1016","volume":"35","author":[{"given":"Sara","family":"Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Chaignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Collin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Dray-Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Weill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.06.030_b0005","unstructured":"European Medicines Agency. EMA confirms evidence does not support that they cause CRPS or POTS. Eur Med Agency; 2015. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/HPV_vaccines_20\/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use\/WC500196773.pdf [Internet]."},{"key":"10.1016\/j.vaccine.2017.06.030_b0010","doi-asserted-by":"crossref","first-page":"d3908","DOI":"10.1136\/bmj.d3908","article-title":"Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe","volume":"343","author":"Dieleman","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2017.06.030_b0015","unstructured":"ECDC, European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation). Stockholm: ECDC; September 2012."},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2796.2011.02467.x","article-title":"Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine","volume":"271","author":"Chao","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.vaccine.2017.06.030_b0025","doi-asserted-by":"crossref","first-page":"f5906","DOI":"10.1136\/bmj.f5906","article-title":"Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study","volume":"347","author":"Arnheim-Dahlstr\u00f6m","year":"2013","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.030_b0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jama.2014.16946","article-title":"Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system","volume":"313","author":"Scheller","year":"2015","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.030_b0035","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/joim.12155","article-title":"Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects","volume":"275","author":"Grimaldi-Bensouda","year":"2014","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.030_b0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.revmed.2014.11.009","article-title":"French health insurance databases: What interest for medical research?","volume":"36","author":"Moulis","year":"2015","journal-title":"Rev M\u00e9decine Interne Fond\u00e9e Par Soci\u00e9t\u00e9 Natl Francaise M\u00e9decine Interne"},{"issue":"9","key":"10.1016\/j.vaccine.2017.06.030_b0045","doi-asserted-by":"crossref","first-page":"e0137733","DOI":"10.1371\/journal.pone.0137733","article-title":"Use of fibrates monotherapy in people with diabetes and high cardiovascular risk in primary care: a French nationwide cohort study based on national administrative databases","volume":"10","author":"Roussel","year":"2015","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.030_b0050","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/pds.3879","article-title":"Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study","volume":"24","author":"Polard","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.vaccine.2017.06.030_b0055","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/gutjnl-2015-309690","article-title":"Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study","volume":"65","author":"Basson","year":"2015","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.030_b0060","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1016\/S2352-3026(15)00027-7","article-title":"Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study","volume":"2","author":"Bouillon","year":"2015","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.vaccine.2017.06.030_b0065","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamasurg.2015.1325","article-title":"Association between total hip replacement characteristics and 3-year prosthetic survivorship: a population-based study","volume":"150","author":"Colas","year":"2015","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0070","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2337\/dc12-0506","article-title":"Does insulin glargine increase the risk of cancer compared with other basal insulins?: a French nationwide cohort study based on national administrative databases","volume":"36","author":"Fagot","year":"2013","journal-title":"Diabetes Care"},{"issue":"13","key":"10.1016\/j.vaccine.2017.06.030_b0075","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","article-title":"Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study","volume":"132","author":"Maura","year":"2015","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.vaccine.2017.06.030_b0080","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jth.13053","article-title":"Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France","volume":"13","author":"Tricotel","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"19","key":"10.1016\/j.vaccine.2017.06.030_b0085","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1016\/j.vaccine.2011.02.064","article-title":"HPV vaccination in France: uptake, costs and issues for the National Health Insurance","volume":"29","author":"Fagot","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.030_b0090","doi-asserted-by":"crossref","first-page":"i2002","DOI":"10.1136\/bmj.i2002","article-title":"Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study","volume":"353","author":"Weill","year":"2016","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.030_b0095","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/pds.3593","article-title":"Post-licensure safety surveillance for human papillomavirus-16\/18-AS04-adjuvanted vaccine: more than 4 years of experience","volume":"23","author":"Angelo","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.vaccine.2017.06.030_b0100","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.autrev.2014.01.054","article-title":"On the relationship between human papilloma virus vaccine and autoimmune diseases","volume":"13","author":"Pellegrino","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.030_b0105","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40264-013-0039-5","article-title":"Safety of human papillomavirus vaccines: a review","volume":"36","author":"Macartney","year":"2013","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2017.06.030_b0110","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000000793","article-title":"An overview of quadrivalent human papillomavirus vaccine safety \u2013 2006 to 2015","author":"Vichnin","year":"2015","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"10.1016\/j.vaccine.2017.06.030_b0115","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10067-014-2846-1","article-title":"A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events","volume":"34","author":"Geier","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.vaccine.2017.06.030_b0120","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2017.06.030_b0125","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.vaccine.2010.09.020","article-title":"Guillain-Barr\u00e9 syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006\u20132009","volume":"29","author":"Souayah","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2017.06.030_b0130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4161\/hv.26292","article-title":"Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States","volume":"10","author":"Ojha","year":"2014","journal-title":"Hum Vaccines Immunother"},{"issue":"13","key":"10.1016\/j.vaccine.2017.06.030_b0135","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.vaccine.2017.01.076","article-title":"No increased risk of Guillain-Barr\u00e9 syndrome after human papilloma virus vaccine: a self-controlled case-series study in England","volume":"35","author":"Andrews","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/cit222","article-title":"Lack of association of Guillain-Barr\u00e9 syndrome with vaccinations","volume":"57","author":"Baxter","year":"2013","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"12","key":"10.1016\/j.vaccine.2017.06.030_b0145","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/archinte.166.12.1301","article-title":"No association between immunization and Guillain-Barr\u00e9 syndrome in the United Kingdom, 1992 to 2000","volume":"166","author":"Hughes","year":"2006","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.vaccine.2017.06.030_b0150","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/pds.3321","article-title":"Risk of Guillain-Barr\u00e9 syndrome after meningococcal conjugate vaccination","volume":"21","author":"Velentgas","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"10.1016\/j.vaccine.2017.06.030_b0155","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S1473-3099(13)70104-X","article-title":"Risk of Guillain-Barr\u00e9 syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study","volume":"13","author":"Kwong","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.030_b0160","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"9876","key":"10.1016\/j.vaccine.2017.06.030_b0165","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(12)62189-8","article-title":"Association between Guillain-Barr\u00e9 syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis","volume":"381","author":"Salmon","year":"2013","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","article-title":"Risk of Guillain-Barr\u00e9 syndrome following H1N1 influenza vaccination in Quebec","volume":"308","author":"De Wals","year":"2012","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.vaccine.2017.06.030_b0175","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/MIB.0b013e318281f34e","article-title":"Risk of inflammatory bowel disease following Bacille Calmette-Gu\u00e9rin and smallpox vaccination: a population-based Danish case-cohort study","volume":"19","author":"Villumsen","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.vaccine.2017.06.030_b0180","doi-asserted-by":"crossref","first-page":"d5956","DOI":"10.1136\/bmj.d5956","article-title":"Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden","volume":"343","author":"Bardage","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.030_b0185","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.crohns.2011.05.010","article-title":"Environmental factors in inflammatory bowel disease: a case-control study based on a Danish inception cohort","volume":"5","author":"Hansen","year":"2011","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.vaccine.2017.06.030_b0190","article-title":"Vaccination and risk for developing inflammatory bowel disease: a meta-analysis of case-control and cohort studies","volume":"13","author":"de Chambrun","year":"2015","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"11","key":"10.1016\/j.vaccine.2017.06.030_b0195","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1080\/21645515.2016.1199308","article-title":"Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16\/18 AS04-adjuvanted vaccine in the United Kingdom","volume":"12","author":"Willame","year":"2016","journal-title":"Hum Vaccines Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0200","first-page":"150","article-title":"The epidemiology of Guillain-Barr\u00e9 syndrome worldwide","volume":"32","author":"McGrogan","year":"2009","journal-title":"A systematic literature review. Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.030_b0210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jnnp.2007.118810","article-title":"CW. Incidence of Guillain-Barr\u00e9 syndrome in Alberta, Canada: an administrative data study","volume":"79","author":"Hauck","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.vaccine.2017.06.030_b0215","article-title":"Guillain-Barr\u00e9 syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008\u20132013)","author":"Delannoy","year":"2016","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.030_b0220","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/aje\/kwr072","article-title":"Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A\/H1N1 viruses","volume":"174","author":"Grimaldi-Bensouda","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.vaccine.2017.06.030_b0225","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"49","key":"10.1016\/j.vaccine.2017.06.030_b0230","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1016\/j.vaccine.2013.09.052","article-title":"Validation of the French national health insurance information system as a tool in vaccine safety assessment: application to febrile convulsions after pediatric measles\/mumps\/rubella immunization","volume":"31","author":"Hanf","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2017.06.030_b0235","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/MOP.0b013e328365ad3f","article-title":"Pediatric Guillain-Barr\u00e9 syndrome","volume":"25","author":"Ryan","year":"2013","journal-title":"Curr Opin Pediatr"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/mus.23749","article-title":"Guillain-Barr\u00e9 syndrome during childhood: particular clinical and electrophysiological features","volume":"48","author":"Devos","year":"2013","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.vaccine.2017.06.030_b0245","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jns5.12068","article-title":"Long-term outcome of Guillain-Barr\u00e9 syndrome in children","volume":"19","author":"Roodbol","year":"2014","journal-title":"J Peripher Nerv Syst JPNS"},{"issue":"4","key":"10.1016\/j.vaccine.2017.06.030_b0250","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2014.07.036","article-title":"Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study","volume":"13","author":"Rungoe","year":"2015","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T07:24:40Z","timestamp":1536045880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17308071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":50,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0264410X17308071"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}